Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-50528
Wick, W; Weller, M; Weiler, M; Batchelor, T; Yung, A W; Platten, M (2011). Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro-Oncology, 13(6):566-579.
View at publisher
Insights into the molecular pathogenesis of glioblastoma have not yet resulted in relevant clinical improvement. With standard therapy, which consists of surgical resection with concomitant temozolomide in addition to radiotherapy followed by adjuvant temozolomide, the median duration of survival is 12-14 months. Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. Recent results of bevacizumab may represent a proof of principle that treatment with targeted agents can result in clinical benefits for patients with glioblastoma. This review discusses limitations in the existing therapy for glioblastoma and provides an overview of current efforts to identify molecular targets using large-scale screening of glioblastoma cell lines and tumor samples. We discuss preclinical and clinical data for several novel molecular targets, including growth factor receptors, phosphatidylinositol-3 kinase, SRC-family kinases, integrins, and CD95 ligand and agents that inhibit these targets, including erlotinib, enzastaurin, dasatinib, sorafenib, cilengitide, AMG102, and APG101. By combining advances in tumor screening with novel targeted therapies, it is hoped that new treatment options will emerge for this challenging tumor type.
61 downloads since deposited on 10 Nov 2011
14 downloads since 12 months
|Item Type:||Journal Article, refereed, further contribution|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Clinic for Neurology|
|Dewey Decimal Classification:||610 Medicine & health|
|Deposited On:||10 Nov 2011 11:43|
|Last Modified:||30 Nov 2013 12:44|
|Publisher:||Oxford University Press|
|Additional Information:||This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Neuro-Oncology following peer review. The definitive publisher-authenticated version Neuro Oncol (2011) 13 (6): 566-579 is available online at: http://dx.doi.org/10.1093/neuonc/nor039|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page